Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Paragraf introduces PMF2000 GFET Zeotap named High Performer in G2 Grid® for Enterprise CDPs (2026) Paragraf and Archer Materials announce strategic collaboration on graphene‑based quantum devices PlanetiQ awarded $15M U.S. Air Force STRATFI contract to advance next-generation weather data from space Glydways raises oversubscribed $170M Series C as first autonomous vehicle networks enter public operation in 2026 Resolve Therapeutics and Institut Pasteur collaborate to identify Cell-Free RNA triggers in autoimmunity
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.

 

Cookie Policy Website powered by 100% renewable energy Privacy Policy